SIGHT GenSight Biologics S.A.

Regulatory News:

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its stock has been included, as of today, in the Enternext® PEA-PME 150 index (ISIN: FR0012246023) following its annual review by the Euronext Indices Department.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190930005713/en/

GenSight Biologics Thomas Gidoin Chief Financial Officer tgidoin@gensight-biologics.com +33 (0)1 76 21 72 20 RooneyPartners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017 Solebury Trout US Investor Relations Chad Rubin crubin@troutgroup.com +1-646-378-2947 James Palmer Europe Investor Relations j.palmer@orpheonfinance.com +33 7 60 92 77 74

GenSight Biologics (EU:SIGHT)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025

GenSight Biologics (EU:SIGHT)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025